וסקפה - Vazkepa
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | C10AX Other lipid modifying agents |
|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | פ××× - PER OS |
| צ×רת ××× ×× | קפס×××ת ר××ת, CAPSULE, SOFT ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | Vazkepa is indicated to reduce the risk of cardiovascular events in adult statin-treated patients at highcardiovascular risk with elevated triglycerides (⥠150 mg/dL [⥠1.7 mmol/L]) and⢠established cardiovascular disease, or⢠diabetes, and at least one other cardiovascular risk factor. |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ××¡×§×¤× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | AMARIN PHARMACEUTICALS IRELAND LIMITED, IRELAND |
| ×©× ××¢× ×ר×ש×× | NEOPHARM (ISRAEL)1996 LTD |
| ר×ש××× | ת×ר×× ××ש×: 1/2022. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 17/06/2024 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־17 ביוני 2024 ב־06:44